ECOG-ACRIN Cancer Research Group
About Us

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a multidisciplinary, membership-based scientific organization that designs and conducts biomarker-driven cancer research involving adults who have or are at risk of developing cancer. The Group is dedicated to its stated purpose, which is to achieve research advances in all aspects of cancer care and thereby reduce the burden of cancer and improve the quality of life and survival in patients.
There are nearly 1300 member institutions in the U.S. and around the world. Approximately 15,000 physicians, translational scientists, and associated research professionals from the member institutions are involved in Group research, along with patient representative members who bring the patient voice to the development of ECOG-ACRIN science.
Our History
ECOG-ACRIN was formed in May 2012 by a merger that combined the complementary strengths of the Eastern Cooperative Oncology Group (ECOG) in cancer therapy and the American College of Radiology Imaging Network (ACRIN) in cancer imaging. ECOG and ACRIN were two highly respected National Cancer Institute-sponsored cancer cooperative groups.
ECOG’s large-scale cancer treatment clinical trials changed the standard of care in numerous types of cancer and helped to individualize cancer therapy. ACRIN’s clinical trials encompassed the full range of medical imaging research, including the investigation of surveillance strategies in high-risk populations, imaging biomarkers in early phase trials, prevention approaches in landmark cancer screening trials, and methodologies in comparative-effectiveness research.
Because of its multidisciplinary membership, ECOG-ACRIN is able to integrate therapeutic and medical imaging research with the latest bioinformatic technologies into a single scientific organization capable of transforming the approach to cancer research and care
Our Leadership
Featured Trials

NCI-MATCH Precision Medicine Trial
NCI-MATCH (EAY131), the largest precision medicine cancer trial to date, seeks to determine whether matching certain drugs or drug combinations in adults whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of their cancer type.

TMIST Breast Cancer Screening Trial
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST or EA1151) is a randomized study that will help us move toward a more personalized breast cancer screening approach, tailoring mammography for each woman based on her own genetics and individual risk factors for developing breast cancer.

EA2185 Pancreatic Cyst Surveillance Study
This study is comparing which approach—less frequent or more frequent monitoring—is better for patients with pancreatic cysts.